Newer treatments for type 2 diabetes are proving effective in the management of the disease, but their list of side effects continues to grow as more patients take the drugs over longer periods of time.
According to Clinical Endocrinology News, the newer classes of diabetes drugs, which includes DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors, have all been linked to potentially serious adverse effects to the skin.
DPP-4 inhibitors, which include the brand names Januvia, Janumet and Tradjenta, have been linked to a condition known as bullous pemphigoid, a rare skin condition that causes large, fluid-filled blisters on areas of the skin that often flex, such as the lower abdomen, upper thighs, or armpits. The condition can be life threatening, especially in older patients and those in poor health.
DPP-4 inhibitors can also cause a condition known as angioedema, the rapid swelling of the skin that affects deeper layers of the skin, often around the eyes and lips. The drugs can also cause peripheral edema, or the accumulation of fluid causing swelling in the lower limbs.
GLP-1 agonists, which includes the brand names Byetta and Victoza, have been linked to injection site reactions in up to 20 percent of patients.
SGLT2 inhibitors, such as Invokana, Farxiga and Jardiance, result in yeast infections in about 10 percent of patients, typically women and uncircumcised men.
DPP-4 inhibitors and GLP-1 agonists – specifically Januvia, Byetta and Victoza – have also been linked to more serious side effects, including a painful inflammation of the pancreas called pancreatitis. The drug have also been linked to an increased risk of pancreatic cancer.
Source: Clinical Endocrinology News